Abstract
Melan-A/MART1 is a melanocytic differentiation antigen recognized on melanoma tumor cells by CD8+ and CD4+ T cells. In this study, we describe a new epitope of this protein recognized in the context of HLA-Cw*0701 molecules by a CD8+ tumor infiltrating lymphocyte (TIL) clone. This CD8+ TIL clone specifically recognized and killed a fraction of melanoma cells lines expressing Melan-A/MART1 and HLA-Cw*0701. We further show that the Melan-A/MART1(51-61) peptide is the optimal peptide recognized by this clone. Together, these data significantly enlarge the fraction of melanoma patients susceptible to benefit from a Melan-A/MART1 vaccine approach.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amino Acid Sequence
-
Antigen Presentation / immunology
-
Antigens, Neoplasm / chemistry
-
Antigens, Neoplasm / genetics
-
Antigens, Neoplasm / immunology*
-
CD8-Positive T-Lymphocytes / immunology*
-
Epitopes, T-Lymphocyte / chemistry
-
Epitopes, T-Lymphocyte / genetics
-
Epitopes, T-Lymphocyte / immunology*
-
Flow Cytometry
-
HLA-C Antigens / immunology*
-
Humans
-
Lymphocyte Activation / immunology
-
Lymphocytes, Tumor-Infiltrating / immunology*
-
MART-1 Antigen
-
Melanoma / immunology*
-
Molecular Sequence Data
-
Neoplasm Proteins / chemistry
-
Neoplasm Proteins / genetics
-
Neoplasm Proteins / immunology*
Substances
-
Antigens, Neoplasm
-
Epitopes, T-Lymphocyte
-
HLA-C Antigens
-
MART-1 Antigen
-
MLANA protein, human
-
Neoplasm Proteins